Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on (1β,2α,4β) Nucleoside. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113880901B reveals a metal-free asymmetric halocyclization route for high-purity nucleoside intermediates, offering significant cost reduction and supply chain reliability.